$ICCT
iCoreConnect Inc. Stock $icct

$icct Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000147793224003018 Filed on May 15, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$2.723M	$0.00
YoY Change
Cost Of Revenue	$513.1K	$491.5K
YoY Change	4.4%	-22.51%
Gross Profit	$2.210M	$1.349M
YoY Change	63.85%	-4.31%
Gross Profit Margin	81.16%
Selling, General & Admin		$842.9K
YoY Change		658.99%
% of Gross Profit		62.48%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$13.53K	$288.9K
YoY Change	-95.32%	-36.61%
% of Gross Profit	0.61%	21.42%
Operating Expenses	$5.252M	$842.9K
YoY Change	523.17%	658.99%
Operating Profit	-$3.042M	-$842.9K
YoY Change	260.94%	659.02%
Interest Expense	$226.5K	$884.9K
YoY Change	-74.41%	-294.2%
% of Operating Profit
Other Income/Expense, Net	-$1.681M	$884.9K
YoY Change	-289.93%	5522.59%
Pretax Income		$42.08K
YoY Change		-144.15%
Income Tax	-$54.00K	$185.8K
% Of Pretax Income		441.63%
Net Earnings	-$5.171M	-$143.8K
YoY Change	3497.12%	3757.07%
Net Earnings / Revenue	-189.87%
Basic Earnings Per Share
Diluted Earnings Per Share		-$0.01
COMMON SHARES
Basic Shares Outstanding		10.16M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments		$229.2K
YoY Change		-76.06%
Cash & Equivalents	$138.0K	$229.2K
Short-Term Investments
Other Short-Term Assets		$175.9K
YoY Change		-53.9%
Inventory
Prepaid Expenses		$175.9K
Receivables	$512.1K	$342.4K
Other Receivables		$0.00
Total Short-Term Assets	$1.370M	$405.0K
YoY Change	238.12%	-69.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$188.9K	$1.009M
YoY Change	-81.27%	-13.82%
Goodwill	$1.485M
YoY Change
Intangibles
YoY Change
Long-Term Investments		$84.19M
YoY Change		2.02%
Other Assets
YoY Change
Total Long-Term Assets	$19.17M	$84.19M
YoY Change	-77.24%	2.02%
TOTAL ASSETS
Total Short-Term Assets	$1.370M	$405.0K
Total Long-Term Assets	$19.17M	$84.19M
Total Assets	$20.54M	$84.60M
YoY Change	-75.73%	0.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$802.3K
YoY Change		884.78%
Accrued Expenses		$155.1K
YoY Change		-85.17%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due	$6.389M	$5.041M
YoY Change	26.73%	183.82%
Total Short-Term Liabilities	$12.28M	$988.1K
YoY Change	1142.36%	1112.88%
LONG-TERM LIABILITIES
Long-Term Debt	$1.195M	$0.00
YoY Change
Other Long-Term Liabilities		$780.6K
YoY Change		2315.35%
Total Long-Term Liabilities	$2.081M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.28M	$988.1K
Total Long-Term Liabilities	$2.081M	$0.00
Total Liabilities	$14.36M	$988.1K
YoY Change	1353.0%	1112.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$120.2M	-$583.3K
YoY Change	20508.49%	491.72%
Common Stock	$1.024K	$211.00
YoY Change	385.31%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.178M	-$583.1K
YoY Change
Total Liabilities & Shareholders Equity	$20.54M	$84.60M
YoY Change	-75.73%	0.87%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$5.171M	-$143.8K
YoY Change	3497.12%	3757.07%
Depreciation, Depletion And Amortization	$13.53K	$288.9K
YoY Change	-95.32%	-36.61%
Cash From Operating Activities	-$990.0K	$207.3K
YoY Change	-577.64%	-152.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$194.1K
YoY Change	-100.0%	206.67%
Acquisitions	$370.0K	$0.00
YoY Change
Other Investing Activities		-$500.0K
YoY Change		-99.39%
Cash From Investing Activities	-$1.204M	-$500.0K
YoY Change	140.9%	-99.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.113M	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-$990.0K	207.3K
Cash From Investing Activities	-$1.204M	-500.0K
Cash From Financing Activities	$1.113M	0.000
Net Change In Cash	-$1.081M	-292.7K
YoY Change	269.44%	-130.57%
FREE CASH FLOW
Cash From Operating Activities	-$990.0K	$207.3K
Capital Expenditures	$0.00	$194.1K
Free Cash Flow	-$990.0K	$13.15K
YoY Change	-7626.46%	-102.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001906133
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4376709	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3755209	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10240398	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10068477	shares
CY2023Q3	us-gaap	Goodwill Goodwill	1484966	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1484966	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2022Q2	icct	Common Stock Issued Value CommonStockIssuedValue	45000	usd
CY2023Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	540000	usd
CY2024Q1	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	0	usd
CY2024Q1	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	0	usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41309
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	iCoreConnect Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2462502
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	529 E. Crown Point Road
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocoee
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34761
CY2024Q1	dei	City Area Code CityAreaCode	888
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	810-7706
CY2024Q1	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	ICCT
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10240398	shares
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138031	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1219358	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	512148	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	563905	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	719347	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1725062	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1369526	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3508325	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188895	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	202421	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1060267	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1122412	usd
CY2024Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	1125368	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	903412	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	6792028	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	0	usd
CY2024Q1	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	2729920	usd
CY2023Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	2980412	usd
CY2024Q1	icct	Forward Purchase Agreement ForwardPurchaseAgreement	5784556	usd
CY2023Q4	icct	Forward Purchase Agreement ForwardPurchaseAgreement	5484556	usd
CY2024Q1	us-gaap	Goodwill Goodwill	1484966	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1484966	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	19166000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12178179	usd
CY2024Q1	us-gaap	Assets Assets	20535526	usd
CY2023Q4	us-gaap	Assets Assets	15686504	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4894053	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3243338	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240705	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	241945	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	6388603	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4720454	usd
CY2024Q1	icct	Related Party Notes Payable Current RelatedPartyNotesPayableCurrent	572127	usd
CY2023Q4	icct	Related Party Notes Payable Current RelatedPartyNotesPayableCurrent	550975	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	180712	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	119598	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12276200	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8876310	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1195432	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1420137	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	886014	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	945889	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2081446	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2366026	usd
CY2024Q1	us-gaap	Liabilities Liabilities	14357646	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11242336	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4376709	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3755209	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	438	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	376	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10240398	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10068477	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1024	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1007	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126386147	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119481543	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120209729	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115038758	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6177880	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4444168	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20535526	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15686504	usd
CY2024Q1	us-gaap	Revenues Revenues	2723363	usd
CY2023Q1	us-gaap	Revenues Revenues	1840371	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	513097	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	491449	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	2210266	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1348922	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4519898	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2411071	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	732553	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	288909	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	5252451	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2699980	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3042185	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1351058	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	226467	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	257913	usd
CY2024Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	1302697	usd
CY2023Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	80063	usd
CY2024Q1	icct	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	300000	usd
CY2023Q1	icct	Change In Fair Value Of Forward Purchase Agreement ChangeInFairValueOfForwardPurchaseAgreement	0	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-54000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Other Expenses OtherExpenses	397621	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	0	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1680785	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-337976	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-4722970	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1689034	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	448000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5170970	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1689034	usd
CY2024Q1	icct	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.51
CY2023Q1	icct	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.26
CY2024Q1	icct	Weighted Average Number Of Shares Basic And Diluted WeightedAverageNumberOfSharesBasicAndDiluted	10100426	shares
CY2023Q1	icct	Weighted Average Number Of Shares Basic And Diluted WeightedAverageNumberOfSharesBasicAndDiluted	6490738	shares
CY2023Q1	icct	Balances Previously Reported Amount BalancesPreviouslyReportedAmount	-2501504	usd
CY2023Q1	icct	Retroactive Application Of Reverse Capitalization Amount RetroactiveApplicationOfReverseCapitalizationAmount	-10243309	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12744813	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	540000	usd
CY2023Q1	icct	Origination Fee In Convertible Debt Agreement Amount OriginationFeeInConvertibleDebtAgreementAmount	80063	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	685333	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	272983	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1689034	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-12855468	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4444168	usd
CY2024Q1	icct	Origination Fee In Convertible Debt Agreement Amount OriginationFeeInConvertibleDebtAgreementAmount	182004	usd
CY2024Q1	icct	Stock Issued For Purchase Of Verifi Dental Limited Amount StockIssuedForPurchaseOfVerifiDentalLimitedAmount	840000	usd
CY2024Q1	icct	Stock Issued For Purchase Of Featherpay Amount StockIssuedForPurchaseOfFeatherpayAmount	4800000	usd
CY2024Q1	icct	Stock Issued For The Purchase Of Teamworx Amount StockIssuedForThePurchaseOfTeamworxAmount	575000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	507679	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5170970	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6177880	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5170970	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1689034	usd
CY2024Q1	us-gaap	Depreciation Depreciation	13526	usd
CY2023Q1	us-gaap	Depreciation Depreciation	5733	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	719028	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	283176	usd
CY2024Q1	icct	Finance Fee FinanceFee	182922	usd
CY2023Q1	icct	Finance Fee FinanceFee	80063	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	123797	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	35982	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	507670	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	272983	usd
CY2024Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	226466	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	15535	usd
CY2024Q1	icct	Change In Fair Value Of Forward Purchase Agreements ChangeInFairValueOfForwardPurchaseAgreements	-300000	usd
CY2023Q1	icct	Change In Fair Value Of Forward Purchase Agreements ChangeInFairValueOfForwardPurchaseAgreements	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16822	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	36449	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1005715	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-56279	usd
CY2024Q1	icct	Increase Decrease In Right Of Use Asset Net Of Lease Liability IncreaseDecreaseInRightOfUseAssetNetOfLeaseLiability	1030	usd
CY2023Q1	icct	Increase Decrease In Right Of Use Asset Net Of Lease Liability IncreaseDecreaseInRightOfUseAssetNetOfLeaseLiability	1981	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1650714	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-192149	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	66894	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	53345	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-990030	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1152215	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	370000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2024Q1	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	500000	usd
CY2023Q1	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40769	usd
CY2024Q1	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	334437	usd
CY2023Q1	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	153346	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1204437	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-194115	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1423093	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2000000	usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	309953	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	586421	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	540000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1113140	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1953579	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1081327	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	607249	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1219358	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	196153	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138031	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	803402	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	74921	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	215821	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. NATURE OF OPERATIONS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">iCoreConnect Inc. (formerly known as FG Merger Corp) (collectively with its subsidiary, the “Company”), a Delaware Corporation, is a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise platform of applications and services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to August 25, 2023, the Company was a special purpose acquisition company formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On August 25, 2023 (the “Closing Date”), the Company consummated the business combination contemplated by the Merger Agreement and Plan of Reorganization by and among FG Merger Corp, a special purpose acquisition company incorporated in Delaware (“FGMC”), FG Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of FGMC (“Merger Sub”), and iCoreConnect Inc., a Nevada corporation(“iCore”), dated as of January 5, 2023 (“Merger Agreement”). Pursuant to the terms of the Merger Agreement, a business combination between FGMC and iCore. was affected through the merger of Merger Sub with and into iCore, with iCore. surviving the merger as a wholly owned subsidiary of FGMC. On the Closing Date, FGMC was renamed “iCoreConnect Inc.” and the previous iCoreConect Inc. was renamed “iCore Midco, Inc.” (“Old iCore”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Business Combinations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 1, 2024 the Company completed the acquisitions for substantial all the assets of (a)Ally Commerce, Inc. dba FeatherPay; (b) Verifi Dental, Limited; and (c) Teamworx LLC which are all accounted for as asset acquisitions. On September 1, 2023, the Company completed the acquisitions for substantially all of the assets of Preferred Dental Development, LLC which was accounted for as an asset acquisition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Going Concern and Liquidity</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended March 31, 2024, the Company generated an operating loss of $3,042,185. In addition, at March 31, 2024, the Company has an accumulated deficit, and net working capital deficit of $120,209,729 and $10,906,674 respectively. The Company’s activities were primarily financed through private placements of equity securities and issuance of debt. The Company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations. The Company is reliant on future fundraising to finance operations in the near future. Such financings may not be available on terms satisfactory to the Company, if at all. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern for a period of 12 months from the issuance date of these financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Currently, management intends to develop an improved healthcare communications system and intends to develop alliances with strategic partners to generate revenues that will sustain the Company. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120209729	usd
CY2024Q1	icct	Working Capital Deficit WorkingCapitalDeficit	-10906674	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	37097	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	102061	usd
CY2024Q1	us-gaap	Financing Receivable Individually Evaluated For Impairment FinancingReceivableIndividuallyEvaluatedForImpairment	105676	usd
CY2024Q1	icct	Recurring Revenues RecurringRevenues	2595050	usd
CY2023	icct	Recurring Revenues RecurringRevenues	1703815	usd
CY2024Q1	icct	Non Recurring Revenues NonRecurringRevenues	128313	usd
CY2023	icct	Non Recurring Revenues NonRecurringRevenues	136556	usd
CY2024Q1	us-gaap	Advertising Expense AdvertisingExpense	208085	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	125048	usd
CY2024Q1	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for derivative instruments in accordance with ASC 815 “Derivatives and Hedging”, which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and preferred stock instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.</p>
CY2024Q1	icct	Financial Instruments With Down Round Featurespolicytextblock FinancialInstrumentsWithDownRoundFeaturespolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows the guidance of FASB ASU 2017-11, “Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); and Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. ASU 2017-11 simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downround adjustment of the current exercise price based on the price of the future equity offerings. The standard requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for the purposes of determining liability of equity classification. Companies that provide earning per share (“EPS”) data will adjust their diluted EPS calculation for the effect of the feature when triggered (i.e. when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity.</p>
CY2024Q1	icct	Beneficial Conversion Features And Warrantspolicttextblock BeneficialConversionFeaturesAndWarrantspolicttextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company evaluates the conversion feature of convertible debt instruments to determine whether the conversion feature was beneficial as described in ASC 470-30, Debt with Conversion and Other Options. The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt that has conversion features at fixed or adjustable rates that are in-the-money when issued and records the relative fair value of any warrants issued with those instruments. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds to the warrants and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion features, both of which are credited to additional paid-in capital. The Company calculates the fair value of warrants with the convertible instruments using the Black-Scholes valuation model.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under these guidelines, the Company first allocates the value of the proceeds received from a convertible debt transaction between the convertible debt instrument and any other detachable instruments included in the transaction (such as warrants) on a relative fair value basis. A BCF is then measured as the intrinsic value of the conversion option at the commitment date, representing the difference between the effective conversion price and the Company’s stock price on the commitment date multiplied by the number of shares into which the debt instrument is convertible. The allocated value of the BCF and warrants are recorded as a debt discount and accreted over the expected term of the convertible debt as interest expense. If the intrinsic value of the BCF is greater than the proceeds allocated to the convertible debt instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible debt instrument.</p>
CY2023Q3	icct	Capital Stock Authorized CapitalStockAuthorized	140000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	17002897	usd
CY2024Q1	us-gaap	Secured Debt Repurchase Agreements SecuredDebtRepurchaseAgreements	12569810	usd
CY2024Q1	icct	Due From Officers Or Stockholders Or Related Party Current DueFromOfficersOrStockholdersOrRelatedPartyCurrent	4433087	usd
CY2024Q1	us-gaap	Sale Leaseback Transaction Historical Cost SaleLeasebackTransactionHistoricalCost	4433087	usd
CY2024Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	-105676	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10541275	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-6551775	usd
CY2023Q4	icct	Finite Lived Intangible Asset Net Carrying Amount FiniteLivedIntangibleAssetNetCarryingAmount	3883824	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16390934	usd
CY2024Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-5743618	usd
CY2024Q1	icct	Finite Lived Intangible Asset Net Carrying Amount FiniteLivedIntangibleAssetNetCarryingAmount	10647316	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	719028	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	283176	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1484966	usd
CY2024Q1	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	usd
CY2024Q1	us-gaap	Goodwill Goodwill	1484966	usd
CY2024Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	100000	shares
CY2024Q1	icct	Redemption Price Per Shares RedemptionPricePerShares	10.69
CY2024Q1	us-gaap	Notes Payable NotesPayable	8047771	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	6337429	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	104167	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2024Q1	us-gaap	Financing Receivable Unamortized Loan Fee Cost FinancingReceivableUnamortizedLoanFeeCost	359569	usd
CY2023Q4	us-gaap	Financing Receivable Unamortized Loan Fee Cost FinancingReceivableUnamortizedLoanFeeCost	196837	usd
CY2024Q1	icct	Total Notes Payable Net Of Financing Costs TotalNotesPayableNetOfFinancingCosts	7584035	usd
CY2023Q4	icct	Total Notes Payable Net Of Financing Costs TotalNotesPayableNetOfFinancingCosts	6140592	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	6388603	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4720455	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1195432	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1420137	usd
CY2023Q3	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1200000	usd
CY2023Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.12	pure
CY2023Q3	us-gaap	Interest Expense InterestExpense	38609	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	85174	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	86747	shares
CY2024Q1	icct	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginning	776328	shares
CY2024Q1	icct	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning	3.75
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.27
CY2024Q1	icct	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted	P9Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q1	icct	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEnding	779328	shares
CY2024Q1	icct	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding	3.73
CY2024Q1	icct	Weighted Average Remaining Contractual Term In Years Ending WeightedAverageRemainingContractualTermInYearsEnding	P7Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	575235	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.72
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2024Q1	icct	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Beginning SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesBeginning	395072	shares
CY2024Q1	icct	Weighted Average Grant Date Fair Value Nonvested Beginning WeightedAverageGrantDateFairValueNonvestedBeginning	3.76
CY2024Q1	icct	Weighted Average Remaining Years To Vest Nonvested Begining WeightedAverageRemainingYearsToVestNonvestedBegining	P8Y
CY2024Q1	icct	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Granted Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsGrantedNumberOfShares	3000	shares
CY2024Q1	icct	Weighted Average Grant Date Fair Value Nonvested Vested WeightedAverageGrantDateFairValueNonvestedVested	1.27
CY2024Q1	icct	Weighted Average Remaining Years To Vest Nonvested Granted WeightedAverageRemainingYearsToVestNonvestedGranted	P9Y9M18D
CY2024Q1	icct	Weighted Average Grant Date Fair Values Nonvested Granted WeightedAverageGrantDateFairValuesNonvestedGranted	3.72
CY2024Q1	icct	Weighted Average Remaining Years To Vest Nonvested Vested WeightedAverageRemainingYearsToVestNonvestedVested	P7Y8M12D
CY2024Q1	icct	Weighted Average Grant Date Fair Values Nonvested Forfeited Expired WeightedAverageGrantDateFairValuesNonvestedForfeitedExpired	0
CY2024Q1	icct	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Ending SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesEnding	204093	shares
CY2024Q1	icct	Weighted Average Grant Date Fair Values Nonvested Ending WeightedAverageGrantDateFairValuesNonvestedEnding	3.76
CY2024Q1	icct	Weighted Average Remaining Years To Vest Nonvested Ending WeightedAverageRemainingYearsToVestNonvestedEnding	P7Y9M18D
CY2024Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	105000	usd
CY2024Q1	icct	Warrants To Be Issued Additional WarrantsToBeIssuedAdditional	69000	shares
CY2024Q1	icct	Number Of Warrants Outstanding Beginning NumberOfWarrantsOutstandingBeginning	45129	shares
CY2024Q1	icct	Weighted Average Exercise Price Of Warrants Beginning WeightedAverageExercisePriceOfWarrantsBeginning	2.09
CY2024Q1	icct	Weighted Average Remaining Life Of Warrants In Years Beginning WeightedAverageRemainingLifeOfWarrantsInYearsBeginning	P4Y9M21D
CY2024Q1	icct	Aggregate Intrinsic Value Of Warrants Beginning AggregateIntrinsicValueOfWarrantsBeginning	0	usd
CY2024Q1	icct	Number Of Warrants Granted NumberOfWarrantsGranted	69000	shares
CY2024Q1	icct	Weighted Average Exercise Price Of Warrants Granted WeightedAverageExercisePriceOfWarrantsGranted	1.36
CY2024Q1	icct	Weighted Average Remaining Life Of Warrants In Years Granted WeightedAverageRemainingLifeOfWarrantsInYearsGranted	P4Y9M3D
CY2024Q1	icct	Weighted Average Exercise Price Of Warrants Exercised WeightedAverageExercisePriceOfWarrantsExercised	0
CY2024Q1	icct	Weighted Average Exercise Price Of Warrants Cancelled WeightedAverageExercisePriceOfWarrantsCancelled	0
CY2024Q1	icct	Number Of Warrants Outstanding Ending NumberOfWarrantsOutstandingEnding	114129	shares
CY2024Q1	icct	Weighted Average Exercise Price Of Warrants Ending WeightedAverageExercisePriceOfWarrantsEnding	1.65
CY2024Q1	icct	Weighted Average Remaining Life Of Warrants In Years Ending WeightedAverageRemainingLifeOfWarrantsInYearsEnding	P4Y8M4D
CY2024Q1	icct	Aggregate Intrinsic Value Of Warrants Ending AggregateIntrinsicValueOfWarrantsEnding	0	usd
CY2024Q1	icct	One Number Of Warrants Outstanding Beginning OneNumberOfWarrantsOutstandingBeginning	425800	shares
CY2024Q1	icct	One Weighted Average Exercise Price Of Warrants Beginning OneWeightedAverageExercisePriceOfWarrantsBeginning	2.00
CY2024Q1	icct	One Weighted Average Remaining Life Of Warrants In Years Beginning OneWeightedAverageRemainingLifeOfWarrantsInYearsBeginning	P9Y8M12D
CY2024Q1	icct	One Weighted Average Exercise Price Of Warrants Granted OneWeightedAverageExercisePriceOfWarrantsGranted	0
CY2024Q1	icct	One Weighted Average Exercise Price Of Warrants Exercised OneWeightedAverageExercisePriceOfWarrantsExercised	0
CY2024Q1	icct	One Weighted Average Exercise Price Of Warrants Expired OneWeightedAverageExercisePriceOfWarrantsExpired	0
CY2024Q1	icct	One Number Of Warrants Outstanding Ending OneNumberOfWarrantsOutstandingEnding	425800	shares
CY2024Q1	icct	One Weighted Average Exercise Price Of Warrants Ending OneWeightedAverageExercisePriceOfWarrantsEnding	2.00
CY2024Q1	icct	One Weighted Average Remaining Life Of Warrants In Years Ending OneWeightedAverageRemainingLifeOfWarrantsInYearsEnding	P9Y4M24D
CY2024Q1	icct	Two Preferred Stock Warrants Outstanding Beginning TwoPreferredStockWarrantsOutstandingBeginning	10122313	shares
CY2024Q1	icct	Two Weightedaverageexercisepriceofwarrantsbeginning TwoWeightedaverageexercisepriceofwarrantsbeginning	11.50
CY2024Q1	icct	One Weighted Average Remaining Life Of Warrant In Years Beginning OneWeightedAverageRemainingLifeOfWarrantInYearsBeginning	P9Y8M12D
CY2024Q1	icct	Two Weightedaverageexercisepriceofwarrantsgranted TwoWeightedaverageexercisepriceofwarrantsgranted	0
CY2024Q1	icct	Two Weightedaverageexercisepriceofwarrantsexercised TwoWeightedaverageexercisepriceofwarrantsexercised	0
CY2024Q1	icct	Two Weightedaverageexercisepriceofwarrantsexpired TwoWeightedaverageexercisepriceofwarrantsexpired	0
CY2024Q1	icct	Two Number Of Warrants Outstanding Ending TwoNumberOfWarrantsOutstandingEnding	10122313	shares
CY2024Q1	icct	Two Weightedaverageexercisepriceofwarrantsending TwoWeightedaverageexercisepriceofwarrantsending	11.50
CY2024Q1	icct	One Weighted Average Remaining Life Of Warrants In Years Ending Balance OneWeightedAverageRemainingLifeOfWarrantsInYearsEndingBalance	P9Y4M24D
CY2024Q1	icct	Three Preferred Stock Warrants Outstanding Beginning ThreePreferredStockWarrantsOutstandingBeginning	1000000	shares
CY2024Q1	icct	Three Weightedaverageexercisepriceofwarrantsbeginning ThreeWeightedaverageexercisepriceofwarrantsbeginning	15.00
CY2024Q1	icct	Three Weighted Average Remaining Life Of Warrants In Years Beginning ThreeWeightedAverageRemainingLifeOfWarrantsInYearsBeginning	P9Y8M12D
CY2024Q1	icct	Three Weightedaverageexercisepriceofwarrantsgranted ThreeWeightedaverageexercisepriceofwarrantsgranted	0
CY2024Q1	icct	Three Weightedaverageexercisepriceofwarrantsexercised ThreeWeightedaverageexercisepriceofwarrantsexercised	0
CY2024Q1	icct	Three Weightedaverageexercisepriceofwarrantsexpired ThreeWeightedaverageexercisepriceofwarrantsexpired	0
CY2024Q1	icct	Three Number Of Warrants Outstanding Ending ThreeNumberOfWarrantsOutstandingEnding	1000000	shares
CY2024Q1	icct	Three Weightedaverageexercisepriceofwarrantsending ThreeWeightedaverageexercisepriceofwarrantsending	15.00
CY2024Q1	icct	Three Weighted Average Remaining Life Of Warrants In Years Ending ThreeWeightedAverageRemainingLifeOfWarrantsInYearsEnding	P9Y4M24D
CY2024Q1	icct	Common Stock Issued Shares CommonStockIssuedShares	291259	shares
CY2024Q1	icct	Common Stock Issued Value CommonStockIssuedValue	600000	usd
CY2024Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1008376	usd
CY2024Q1	us-gaap	Other Commitment OtherCommitment	1422461	usd
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	5300000	usd
CY2024Q1	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	1210000	usd
CY2024Q1	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	700000	usd
CY2024Q1	us-gaap	Cash Cash	0	usd
CY2024Q1	us-gaap	Cash Cash	871	usd
CY2024Q1	us-gaap	Cash Cash	12752	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	959	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	54259	usd
CY2024Q1	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	0	usd
CY2024Q1	us-gaap	Real Estate Acquired Through Foreclosure RealEstateAcquiredThroughForeclosure	5299041	usd
CY2024Q1	us-gaap	Real Estate Acquired Through Foreclosure RealEstateAcquiredThroughForeclosure	1154870	usd
CY2024Q1	us-gaap	Real Estate Acquired Through Foreclosure RealEstateAcquiredThroughForeclosure	678548	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	8700	usd
CY2024Q1	us-gaap	Acquired Finite Lived Intangible Asset Residual Value AcquiredFiniteLivedIntangibleAssetResidualValue	5300000	usd
CY2024Q1	us-gaap	Acquired Finite Lived Intangible Asset Residual Value AcquiredFiniteLivedIntangibleAssetResidualValue	1210000	usd
CY2024Q1	us-gaap	Acquired Finite Lived Intangible Asset Residual Value AcquiredFiniteLivedIntangibleAssetResidualValue	700000	usd
CY2024Q1	us-gaap	Assets Net AssetsNet	5300000	usd
CY2024Q1	us-gaap	Assets Net AssetsNet	1210000	usd
CY2024Q1	us-gaap	Assets Net AssetsNet	700000	usd

Files In Submission

Name	View Source	Status
0001477932-24-003018-index-headers.html	Edgar Link	pending
0001477932-24-003018-index.html	Edgar Link	pending
0001477932-24-003018.txt	Edgar Link	pending
0001477932-24-003018-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
icct-20240331.xsd	Edgar Link	pending
icct_10q.htm	Edgar Link	pending
icct_ex1010.htm	Edgar Link	pending
icct_ex311.htm	Edgar Link	pending
icct_ex312.htm	Edgar Link	pending
icct_ex321.htm	Edgar Link	pending
icct_ex322.htm	Edgar Link	pending
icct_ex45.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
icct-20240331_def.xml	Edgar Link	unprocessable
icct-20240331_lab.xml	Edgar Link	unprocessable
icct-20240331_pre.xml	Edgar Link	unprocessable
icct_10q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
icct-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCT
iCoreConnect Inc. Stock $icct

2024 Q1 Form 10-Q Financial Statement

#000147793224003018 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCT iCoreConnect Inc. Stock $icct

2024 Q1 Form 10-Q Financial Statement

#000147793224003018 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCT
iCoreConnect Inc. Stock $icct